haloperidol krka 2 mg tablete
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - haloperidol - tableta - 2 mg - urbroj: svaka tableta sadrži 2 mg haloperidola
haloperidol krka 5 mg/1 ml otopina za injekciju
krka farma d.o.o. sarajevo - галоперидол - otopina za injekciju - 5 mg/1 ml - 1 ml otopine za injekciju sadrži: 5 mg haloperidol
haloperidol krka depo 50 mg/1 ml otopina za injekciju
krka farma d.o.o. sarajevo - галоперидол - otopina za injekciju - 50 mg/1 ml - 1 ml otopine za injekciju sadrži: 50 mg haloperidol (u obliku haloperidol dekanoata)
haloperidol krka 2 mg/1 tableta tableta
krka farma d.o.o. sarajevo - галоперидол - tableta - 2 mg/1 tableta - 1 tableta sadrži: 2 mg haloperidola
haloperidol krka 10 mg/1 tableta tableta
krka farma d.o.o. sarajevo - галоперидол - tableta - 10 mg/1 tableta - 1 tableta sadrži: 10 mg haloperidola
haldol depo 50mg/ml rastvor za injekciju
dio stranog druŠtva "krka d.d. novo mesto" slovenija - predstavniŠtvo podgorica - haloperidol - rastvor za injekciju - 50mg/ml
haloperidol zdravlje 2mg tableta
"evropa lek pharma" doo podgorica - haloperidol - tableta - 2mg
haloperidol zdravlje 10mg tableta
"evropa lek pharma" doo podgorica - haloperidol - tableta - 10mg
exolak 50 mg/ml ljekoviti lak za nokte
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - amorolfinklorid - ljekoviti lak za nokte - 50 mg/ml - urbroj: jedan ml sadrži 55,7 mg amorolfinklorida, što odgovara 50 mg amorolfina (5% w/v amorolfina)
adempas
bayer ag - riociguat - hipertenzija, plućna - antihipertenzivi za plućnu arterijsku hipertenziju - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitost je dokazana u populaciji uh uključujući etiologija idiopatskom ili nasljedne ili uh uh, povezane s bolestima vezivnog tkiva . paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.